Sign Up For Our FREE E-mail Newsletter-> HERE <-To Receive Our Penny Stock Expert Picks Now!
Visit our Twitter page for real-time updates, click here: Penny Stock Experts
Hi Everyone & Welcome New Subscribers,
For those of you who have been following along the ride with us in TPIV (TapImmune, Inc.) over the past couple months, one of the key pieces of news we were looking for was released within the last 10 minutes of today’s session.
The company announced the FDA has granted Orphan Drug Designation (ODD) for it’s cancer vaccine TPIV 200 in the treatment of ovarian cancer.
Read the full press release, HERE, for yourself.
It wasn’t until less than 10 minutes before the closing bell the company released this news, which should make for an exciting morning Thursday given the company will also be presenting at the San Antonio Breast Cancer Symposium between 7:30-9:00AM EST.
We expect TPIV might have even more exciting news regarding a potential big pharma partnership within the next several weeks, but will reassess our point of view following tomorrow’s session.
If TPIV can break above it’s most recent high of .97, and breach the $1.00 level shortly after, we might see a true double from our multiple alerts near .60 over the past month, which would make for a fine way to end the year.
Sign up-> NOW <-To Join Our E-mail List!
Please read our legal Disclaimer below:
We continue trade up to 100,000 shares of TPIV which we have purchased on the open market with our own money. We have no communication with the company nor any affiliates. We may add to this position or sell it entirely at any time. We have no position at this time.
Neither Todayspickis.com nor any of its employees, affiliates, subsidiaries, or family members are registered investment advisers or registered st ock brokers either within the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority and shall not be liable for any direct, indirect, incidental, special or consequential damages arising out of, or resulting from the use or inability to use this site, including but not limited to damages for the loss of capital, funds, profits, use, data, or any and all other possible damages, even if such party has been advised of the possibility of such damages resulting from the use of this site and all information contained on this site.
We are neither licensed nor qualified to provide investment advice. The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the company’s profiled based solely on information contained in our newsletter or website.
Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research. Todayspickis.com may buy or sell shares on the open market that may positively or negatively affect the stock price before or after this mailing and subscribers are to be fully aware that Todayspickis.com and it’s affiliates can buy or sell more shares at any time. We can add or decrease this position at anytime following this e-mail or post. Todayspickis.com and/or it’s affiliates may receive compensation for e-mail alerts.
To view our full compensation disclosure please visit www.Todayspickis.com/Disclaimer.html. Todayspickis.com does not accept free-trading shares as a form of payment.